Federman & Sherwood Announces the Filing of a Securities Class Action Lawsuit against Esperion Therapeutics, Inc.

To join this class action, please complete the following Investor Certification.

Esperion Therapeutics, Inc. [NASDAQ: ESPR] Investor Certification

Company Name
Plaintiff Certifies That:
The following information is true and correct to the best of my knowledge, information and belief: 1. I have reviewed the Complaint in this action and authorize the filing of this Certification as an exhibit to the Complaint, or any substantively similar complaint or amended complaint to be filed in the future. I retain the law office of Federman & Sherwood, and any other counsel with whom Federman & Sherwood deems appropriate to associate with, to pursue this action on my behalf on a contingency fee basis. 2. If chosen, I am willing to serve as a representative party on behalf of the class (the “Class”), either individually or as part of a group on behalf of the Class as defined in the Complaint, including providing testimony at deposition or trial (if necessary). I am also willing to participate on an executive committee of shareholders.
3. I have made the following transaction(s) during the Class Period in
securities (which are the subject of this action) as follows:
# Shares Purchased Date Of Purchase Price Paid Per Share Class Of Stock (e.g. Common) If Sold, # Of Shares Sold Date Sold (If Sold) Per Share Selling Price
4. I did not purchase these securities at the direction of my attorney or in order to participate in a lawsuit under the Securities Act of 1933 or the Securities Exchange Act of 1934. 5. During the 3-year period preceding the date of this Certification, I have not sought to serve, nor have I served, as a representative to any party or on behalf of any class in any action arising under the Securities Act of 1933 or the Securities Exchange Act of 1934. 6. I will not accept any payment if chosen to serve as a representative party on behalf of the Class beyond my pro rata share of an award to the Class, or as otherwise ordered and approved by the Court, except for such reasonable costs and expenses directly relating to my service as a representative of the Class and as ordered and approved by the Court.
Signed under penalty of perjury, under the laws of the United States of America on:*
MM slash DD slash YYYY
Investor Signature*
Please type: /s/ Your Full Name (e.g. /s/ John Doe)
Print Name*
Type Full Name Here
*
Home Address City State Zip
Home Telephone Number
Cell Telephone Number
Email Address
Secondary Email Address (if any)
By clicking on the button below, I intend to sign and execute this agreement and retain Federman & Sherwood to proceed on Plaintiff’s behalf on a contingency basis.

Oklahoma City, OK (May 10, 2018) – On May 7, 2018, a securities class action lawsuit was filed in the United States District Court for the District of Michigan against Esperion Therapeutics, Inc. (NASDAQ: ESPR). The complaint alleges violations of federal securities laws, Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5, including allegations of issuing a series of material or false misrepresentations to the market which had the effect of artificially inflating the market price during the Class Period, which is February 22, 2017 through May 1, 2018. More specifically, the Complaint alleges that defendants during the Class Period made materially false and/or misleading statements and/or failed to disclose that: (1) Esperion’s cholesterol-lowering medication, bempedoic acid, entailed serious undisclosed safety risks, including death; and (2) as a result, Esperion’s public statements were materially false and misleading at all relevant times.

On May 2, 2018, Esperion announced results from its second Phase 3 study for its cholesterol-lowering medication bempedoic acid. Esperion reported that while the trial met the primary endpoint of safety and tolerability and the key efficacy endpoint, there were 13 deaths in the treatment group compared to only two in the control group. On this news, Esperion’s share price fell from a close of $70.50 per share on May 1, 2018, to a close of $45.75 per share the following day.

Plaintiff seeks to recover damages on behalf of all Esperion Therapeutics, Inc. shareholders who purchased common stock during the Class Period and are therefore a member of the Class as described above. You may move the Court no later than Friday, July 6, 2018 to serve as a lead plaintiff for the entire Class. However, in order to do so, you must meet certain legal requirements pursuant to the Private Securities Litigation Reform Act of 1995.

News & Current Cases

Federman & Sherwood Announces the Filing of a Securities Class Action Lawsuit against Esperion Therapeutics, Inc.

Esperion Therapeutics, Inc. [NASDAQ: ESPR] Investor Certification

Plaintiff Certifies That:

Categories

let’s connect

OKLAHOMA Office

TEXAS Office

# Shares Purchased	Date Of Purchase	Price Paid Per Share	Class Of Stock (e.g. Common)	If Sold, # Of Shares Sold	Date Sold (If Sold)	Per Share Selling Price